Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
23.05. | Avalon GloboCare droht Delisting von der Nasdaq wegen Eigenkapitalmangel | 2 | Investing.com Deutsch | ||
23.05. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
13.05. | Avalon GloboCare Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
AVALON GLOBOCARE Aktie jetzt für 0€ handeln | |||||
29.04. | Avalon GloboCare Corp. - 8-K, Current Report | - | SEC Filings | ||
24.04. | Avalon GloboCare Corp. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
10.04. | Avalon GloboCare sichert Patent für CAR-T, CAR-NK Technologie in China | 1 | Investing.com Deutsch | ||
10.04. | Avalon GloboCare secures patent for CAR-T, CAR-NK technology in China | 2 | Investing.com | ||
10.04. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
01.04. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
01.04. | Avalon GloboCare Corp.: Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series | 1 | GlobeNewswire (USA) | ||
31.03. | Avalon GloboCare Corp. - 10-K, Annual Report | 4 | SEC Filings | ||
10.03. | Avalon GloboCare Corp. - 8-K, Current Report | 2 | SEC Filings | ||
27.02. | Avalon GloboCare Corp. - 8-K, Current Report | 2 | SEC Filings | ||
18.02. | Avalon GloboCare secures patent in China for CAR therapy tech | 2 | Investing.com | ||
18.02. | Avalon GloboCare sichert sich Patent in China für CAR-Therapie-Technologie | 4 | Investing.com Deutsch | ||
18.02. | Avalon GloboCare Corp.: Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China | 154 | GlobeNewswire (Europe) | FREEHOLD, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced... ► Artikel lesen | |
18.02. | Avalon GloboCare Corp. - 8-K, Current Report | - | SEC Filings | ||
10.01. | Avalon GloboCare Corp. - 8-K, Current Report | - | SEC Filings | ||
19.12.24 | Avalon GloboCare Corp. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 99,35 | +1,90 % | Onkologie: Milliarden-Deal für BioNTech | Die Aktie des Biotechnologie-Unternehmens springt am Montagmittag zweistellig an. Auslöser ist eine Partnerschaft mit Bristol Myers Squibb. Der Deal zielt auf einen Hoffnungsträger aus der Onkologie-Pipeline... ► Artikel lesen | |
EVOTEC | 7,150 | +0,08 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CUREVAC | 3,950 | +1,23 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
AMGEN | 252,35 | +0,34 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,500 | +0,60 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
IDEXX LABORATORIES | 463,70 | +0,83 % | Jim Cramer on IDEXX Laboratories, Inc. (IDXX): "I Just Can't Get My Arms Around It" | ||
NUREXONE BIOLOGIC | 0,478 | +5,75 % | Breaking News: NurExone gibt die Planung und Details der klinischen Humanstudie mit ExoPTEN bekannt! | ||
IBIO | 0,990 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results | SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.... ► Artikel lesen | |
ARROWHEAD PHARMACEUTICALS | 14,860 | +1,33 % | Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' | ||
COHERUS ONCOLOGY | 0,693 | -0,46 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders ... | DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical... ► Artikel lesen | |
ADAPTIMMUNE THERAPEUTICS | 0,248 | -1,59 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
VOYAGER THERAPEUTICS | 2,948 | +1,45 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
ANAVEX LIFE SCIENCES | 6,896 | +1,98 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report |